SCHEMBL4098709

SCHEMBL4098709

CN(C)CCCOc1cc(-c2nc(Cl)nc3[nH]cnc23)c(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 8/20 0.44
KCNH2 Q12809 3/20 0.37
HSP90AA1 P07900 3/20 0.37
MAOA P21397 2/20 0.34
ALDH1A1 P00352 2/20 0.33
MAOB P27338 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
IGF1R P08069 1/20 0.33
MAPK8 P45983 1/20 0.33
SUV39H2 Q9H5I1 3/20 0.33
CYP2C19 P33261 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091000 0.86 HSP90AB1 (0.51) HSP90AB1KCNH2HSP90AA1KDM4ECYP2C19
SCHEMBL4094869 0.79 HSP90AB1 (0.46) HSP90AB1KCNH2HSP90AA1ALDH1A1KDM4E
SCHEMBL4094713 0.79 HSP90AB1 (0.51) HSP90AB1KCNH2HSP90AA1SMN1; SMN2KDM4E
SCHEMBL4084482 0.77 L3MBTL1 (0.41) ALDH1A1SMN1; SMN2KDM4ECYP2C19
SCHEMBL4101361 0.76 CCR5 (0.37) HSP90AB1KCNH2HSP90AA1SMN1; SMN2CYP2C19
SCHEMBL4089765 0.74 IDH1 (0.39) HSP90AB1KCNH2HSP90AA1ALDH1A1KDM4E
SCHEMBL4101363 0.70 YTHDC1 (0.47) HSP90AB1HSP90AA1
SCHEMBL4259002 0.69 XDH (0.32) HSP90AB1ALDH1A1KDM4ECYP2C19KDR
SCHEMBL13765755 0.69 KDM4E (0.35) HSP90AB1ALDH1A1KDM4ELMNATDP1
SCHEMBL4089680 0.68 DPP4 (0.46) HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P HSP90AB1 2/4885KCNH2 3508/4885HSP90AA1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.